Table 4.
Comparison of laboratory data and PAT ratio between treatment with azelnidipine and amlodipine
| Baseline | Azelnidipine N = 17 |
Amlodipine N = 17 |
P ** | |
|---|---|---|---|---|
| TC, mg/dL | 191 ± 17 | 194 ± 22 | 191 ± 23 | 0.617 |
| LDL-C, mg/L | 109 ± 19 | 111 ± 24 | 110 ± 19 | 0.730 |
| HDL-C, mg/dL | 57 ± 17 | 58 ± 18 | 57 ± 17 | 0.437 |
| Triglyceride, mg/dL | 104 ± 60 | 110 ± 57 | 114 ± 65 | 0.750 |
| HbA1c, % | 5.1 ± 0.3 | 5.1 ± 0.2 | 5.1 ± 0.3 | 0.999 |
| hs-CRP, mg/L | 1.14 ± 2.66 | 0.36 ± 0.23 | 0.74 ± 0.76 | 0.067 |
| Interleukin-6, pg/mL | 1.31 ± 0.61 | 1.44 ± 0.73 | 1.81 ± 0.77 | 0.035 |
| eGFR, ml/min/1.73 m2 | 83.2 ± 18.3 | 82.3 ± 16.1 | 79.4 ± 15.8 | 0.188 |
| L-FABP/U-Cr, ng/g Cr | 29.4 ± 40.0 | 13.9 ± 16.2 | 17.9 ± 16.9 | 0.187 |
| Micro-alb/U-Cr, mg/g Cr | 23.6 ± 47.4 | 26.6 ± 59.9 | 38.0 ± 87.4 | 0.120 |
| HPC,/μL | 2.79 ± 1.67 | 3.56 ± 1.59* | 2.65 ± 1.17 | 0.016 |
| PAT ratio | 1.93 ± 0.34 | 2.05 ± 0.39 | 2.11 ± 0.47 | 0.587 |
Data are mean ± SD. TC; total cholesterol, LDL-C; low-density lipoprotein cholesterol, HDL-C; high-density lipoprotein cholesterol, Hb; hemoglobin, hs-CRP; high sensitivity C-reactive protein, BNP; brain natriuretic peptide, eGFR; estimated glomerular filtration ratio, GFR(ml/min/1.73 m2) L-FABP, L-type fatty acid binding protein, alb; albuminuria, U-Cre; urine creatinine, HPC; hematopoietic progenitor cell, PAT: peripheral arterial tonometry. * P < 0.05 vs. baseline. ** azelnidipine vs. amlodipine.